NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Nuvation Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.48+0.03 (+0.67%)
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
Nuvation Bio Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue [Member] | $23.20M | $18.50M | $15.70M | $7.70M | $421.00K | $779.00K | – | – | – | 73.2% | +5410.7% |
| Product [Member] | $23.19M | $18.51M | $15.70M | $7.72M | $1.24M | $0 | $0 | $0 | $0 | 73.2% | +1773.3% |
| License [Member] | $8.50M | $64.72M | $26.16M | $5.40M | $3.60M | $3.08M | $5.71M | $727.00K | $1.44M | 26.8% | +136.3% |
| Research And Development Service Revenue [Member] | – | – | – | – | – | $2.06M | $3.63M | $727.00K | $1.44M | – | – |
| Royalty Revenue [Member] | – | – | – | – | – | $249.00K | – | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $23.19M | $77.39M | $15.70M | $7.72M | $1.24M | $0 | $0 | $0 | – | 73.2% | +1773.3% |
| China | $7.99M | $5.19M | $972.00K | $2.18M | $3.35M | $2.90M | $3.99M | $65.00K | $1.10M | 25.2% | +138.3% |
| Japan | $504.00K | $652.00K | $25.19M | $3.21M | $241.00K | $183.00K | $1.72M | $662.00K | $340.00K | 1.6% | +109.1% |
| China and Japan [Member] | – | – | – | – | – | – | – | – | $1.10M | – | – |
From the segment and revenue-disaggregation notes of Nuvation Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.